<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="89100">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01982552</url>
  </required_header>
  <id_info>
    <org_study_id>APPEAL</org_study_id>
    <nct_id>NCT01982552</nct_id>
  </id_info>
  <brief_title>An Observational Study to Assess Patient Satisfaction and Control of Psoriasis With Calcipotriene/Betamethasone Dipropionate (Taclonex®) Topical Suspension, and Effect on Quality of Life</brief_title>
  <official_title>An Observational Study to Assess Patient Satisfaction and Control of Psoriasis With Calcipotriene/Betamethasone Dipropionate (Taclonex®) Topical Suspension, and Effect on Quality of Life</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to document quality of life, patient satisfaction, effect on
      itching, and control of psoriasis vulgaris associated with use of
      calcipotriene/betamethasone dipropionate (Taclonex®) topical suspension 0.005% / 0.064% for
      treatment of plaque psoriasis under real-life conditions.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Dermatology Life Quality Index (DLQI)</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean change from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale for itching</measure>
    <time_frame>2 and 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean percent change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Assessment (PGA)</measure>
    <time_frame>2 and 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent of subjects with controlled disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dermatology Life Quality Index (DLQI)</measure>
    <time_frame>2 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Satisfaction Questionnaire for Medication (TSQM)-9</measure>
    <time_frame>2 and 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dermatology Life Quality Index (DLQI)</measure>
    <time_frame>2 and 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent of patients that have a 5 point or greater change in total score</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients attending a hospital outpatient clinic or the private practice of a
        board-certified dermatologist, dermatology-certified nurse practitioner or physician
        assistant trained in dermatology
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed and dated informed consent obtained prior to any study related activities

          2. Aged 18 years or above

          3. Either sex

          4. Any race or ethnicity

          5. Attending a hospital outpatient clinic or the private practice of a board-certified
             dermatologist, dermatology-certified nurse practitioner or physician assistant
             trained in dermatology

          6. Clinical diagnosis of psoriasis vulgaris involving scalp and/or body amenable to
             treatment with a maximum of 100 g of topical medication per week.

          7. Patients who receive a prescription of calcipotriene/betamethasone dipropionate
             (Taclonex®) topical suspension 0.005% / 0.064% as per an investigator's clinical
             judgment and in accordance with the US label, and who have access to the medication

          8. Able to communicate with the investigator, read and understand English, and
             understand and comply with the requirements of the study

        Exclusion Criteria:

          1. Prior treatment with calcipotriene/betamethasone dipropionate (Taclonex®) topical
             suspension, 0.005%/0.064%.

          2. Contraindications or any warnings/precautions according to the US label.

          3. Current participation in any other interventional clinical study.

          4. Females who are pregnant, breast-feeding, or females of child-bearing potential
             wishing to become pregnant during the study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jerry Bagel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Psoriasis Treatment Center of Central New Jersey, East Windsor, NJ</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alliance Dermatology and Mohs Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Dermatology Clinical Research</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Alliance Dermatology</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Associates and Research</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Melissa Knuckles Dermatology</name>
      <address>
        <city>Corbin</city>
        <state>Kentucky</state>
        <zip>40701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grekin Skin Institute</name>
      <address>
        <city>Warren</city>
        <state>Michigan</state>
        <zip>48088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bettencourt Skin Center</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Las Vegas Skin and Cancer Clinic</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psoriasis Treatment Center of Central NJ</name>
      <address>
        <city>East Windsor</city>
        <state>New Jersey</state>
        <zip>08520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Specialty Dermatology</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Studies</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West End Dermatology</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 12, 2013</lastchanged_date>
  <firstreceived_date>November 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Plaque psoriasis</keyword>
  <keyword>calcipotriene</keyword>
  <keyword>betamethasone dipropionate</keyword>
  <keyword>topical</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Betamethasone sodium phosphate</mesh_term>
    <mesh_term>Calcipotriene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
